Jwcar029
Mantle Cell Lymphoma (MCL)
Sun Yat-sen UniversityCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
172 Active assets in the Mantle Cell Lymphoma (MCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Ruijin Hospital | Phase 4 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BBB |
Bendamustine Czech Lymphoma Study Group | Phase 2 | BBB |
VINCRISTINE SULFATE M.D. Anderson Cancer Center | Phase 2 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Jwcar029 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →